Table 1. Breast cancer recurrence governed by cell cycle regulated genes*.
| Gene name | Incidence of patient's recurrence | Expression median | Fold change | P-value | Gene rank | Reference |
|---|---|---|---|---|---|---|
| CCNE2 | No Recurrence at 3 Years (N = 6) | −1.381 | 0.03 | 467 (in top 3%) | Esserman et al., 2012 | |
| Recurrence at 3 Years (N = 3) | −0.654 | Esserman et al., 2012 | ||||
| CENPA | 1. No Recurrence at 3 Years (N = 10) | –0.44 | 1.76E-04 | 20 (in top 1%) | Desmedt et al., 2007 | |
| 2. Recurrence at 3 Years (N = 3) | 1.197 | |||||
| 1. No Recurrence at 5 Years (N = 9) | –0.707 | 2.29E-04 | 24 (in top 1%) | Desmedt et al., 2007 | ||
| 2. Recurrence at 5 Years (N = 3) | 1.197 | |||||
| 1. Alive at 3 Years (N = 77) | –134 | 0.002 | 187 (in top 1%) | Esserman et al., 2012 | ||
| 2. Dead at 3 Years (N = 15) | –0.355 | |||||
| 1. Alive at 5 Years (N = 21) | –1.807 | 2.12E-04 | 26 (in top 1%) | Esserman et al., 2012 | ||
| 2. Dead at 5 Years (N = 20) | –566 | |||||
| 1. No Recurrence at 3 Years (N = 78) | 1.373 | 0.01 | 380 (in top 2%) | Loi et al., 2007 | ||
| 2. Recurrence at 3 Years (N = 8) | 2.246 | |||||
| 1. No Recurrence at 5 Years (N = 66) | –0.062 | 0.007 | 471 (in top 3%) | Loi et al., 2008 | ||
| 2. Recurrence at 5 Years (N = 10) | 0.604 | |||||
| LIN9 | No Recurrence at 3 Years (N = 69) | 0.418 | 0.009 | 589 (in top 4%) | Esserman et al., 2012 | |
| Recurrence at 3 Years (N = 24) | 0.722 | |||||
| 1. No Recurrence at 5 Years (N = 8) | 0.594 | 0.011 | 924 (in top 5%) | Finak et al., 2008 | ||
| 2. Recurrence at 5 Years (N = 11) | 1.149 | |||||
| RUNDC1 | 1.442 | 0.151 | 5579 | TCGA Breast (database) | ||
| –1.059 | 0.52 | 8666 | Radvanyi et al., 2005 | |||
| –1.061 | 0.592 | 13627 | Bittner (database) | |||
| BRCA2 | Recurrence at 3 years (N = 4) | 0.596 | 0.014 | 516 top 3% | Loi et al., 2008 | |
| No Recurrence at 3 years (N = 72) | –0.076 | Loi et al., 2008 | ||||
| Recurrence or metastasis at 5 years (N = 6) | 0.639 | 4.83E-04 | 87 top 1% | Loi et al., 2008 | ||
| No Recurrence or metastasis at 5 years (N = 69) | –0.09 | Loi et al., 2008 | ||||
| Recurrence at 5 Years (N = 10) | –0.257 | 0.043 | 861 top 6% | Ma et al., 2003 | ||
| No Recurrence at 5 Years (N = 22) | –1.602 | Ma et al., 2003 | ||||
| Recurrence at 3 Years (N = 3) | –1.427 | 0.038 | 958 top 8% | Desmedt et al., 2007 | ||
| No Recurrence at 3 Years (N = 10) | –2.141 | Desmedt et al., 2007 | ||||
| CCNB1 | Recurrence or metastasis at 3 years (N = 8) | 3.124 | 0.002 | 103 top 1% | Loi et al., 2007 | |
| No Recurrence or metastasis at 3 years (N = 78) | 2.465 | Loi et al., 2007 | ||||
| Recurrence or metastasis at 5 years (N = 14) | 3.124 | 0.023 | 1306 top 7% | Loi et al., 2007 | ||
| No Recurrence or metastasis at 5 years (N = 68) | 2.465 | Loi et al., 2007 | ||||
| No Recurrence at 3 Years (N = 71) | –0.04 | 0.018 | 487 (in top 3%) | Loi et al., 2008 | ||
| Recurrence at 3 Years (N = 5) | 0.853 | Loi et al., 2008 | ||||
| No Recurrence at 3 Years (N = 10) | 1.338 | 0.046 | 1130 (in top 9%) | Desmedt et al., 2007 | ||
| Recurrence at 3 Years (N = 3) | 2.709 | Desmedt et al., 2008 | ||||
| CDC25A | No Recurrence at 1 Year (N = 269) | –1.985 | 0.002 | 312 (in top 3%) | Esserman et al., 2012 | |
| Recurrence at 1 Year (N = 16) | –0.749 | Esserman et al., 2012 | ||||
| No Recurrence at 3 Years (N = 217) | –2.08 | 6.83E-04 | 532 (in top 5%) | Esserman et al., 2012 | ||
| Recurrence at 3 Years (N = 68) | –1.078 | Esserman et al., 2012 | ||||
| 1. No Recurrence at 3 Years (N = 10) | –2.893 | 0.002 | 94 (in top 1%) | Esserman et al., 2012 | ||
| 2. Recurrence at 3 Years (N = 3) | –0.037 | Esserman et al., 2012 | ||||
| CDC25C | No Recurrence at 3 Years (N = 10) | –0.706 | 0.002 | 79 (in top 1%) | Loi et al., 2007 | |
| Recurrence at 3 Years (N = 3) | –0.12 | Loi et al., 2007 | ||||
| No Recurrence at 5 Years (N = 9) | –0.879 | 0.002 | 82 (in top 1%) | Desmedt et al., 2007 | ||
| Recurrence at 5 Years (N = 3) | –0.12 | Desmedt et al., 2007 | ||||
| No Recurrence at 3 Years (N = 78) | 0.193 | 0.006 | 245 (in top 2%) | Loi et al., 2007 | ||
| Recurrence at 3 Years (N = 8) | 0.893 | Loi et al., 2008 | ||||
| No Recurrence at 5 Years (N = 68) | 0.138 | 0.002 | 118 (in top 1%) | Loi et al., 2009 | ||
| Recurrence at 5 Years (N = 14) | 0.893 | Loi et al., 2010 | ||||
| No Recurrence at 3 Years (N = 6) | –1.563 | 0.038 | 917 (in top 5%) | Esserman et al., 2012 | ||
| Recurrence at 3 Years (N = 5) | –0.795 | Esserman et al., 2013 | ||||
| CDKN2D | No Recurrence at 5 Years (N = 68) | 0.405 | 0.009 | 584 (in top 3%) | Loi et al., 2007 | |
| Recurrence at 5 Years (N = 14) | 0.6 | |||||
| No Recurrence at 3 Years (N = 229) | –0.051 | 0.001 | 491 (in top 4%) | van de Vijver et al., 2002 MammaPrint® |
||
| Recurrence at 3 Years (N = 63) | 0.01 | MammaPrint 70-gene list | ||||
| No Recurrence at 5 Years (N = 68) | –0.059 | 9.53E-04 | 489 (in top 4%) | van de Vijver et al., 2002 MammaPrint® |
||
| Recurrence at 5 Years (N = 14) | 0.006 |
*Novel phase-related genes in red on A column.